Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Kansas Private Foundation through KU Endowment |
---|---|
Information provided by: | University of Kansas |
ClinicalTrials.gov Identifier: | NCT00302731 |
Double blind placebo controlled pilot study comparing bioidentical 'natural' hormones to low-dose PremPro. Forty participants will be enrolled. The purpose of this study is to try to gather early information about safety when "natural" or bioidentical hormones are used during early menopause.
Condition | Intervention | Phase |
---|---|---|
Menopause |
Drug: Prempro Drug: estradiol, estriol, progesterone Drug: estriol, progesterone Drug: estradiol, progesterone |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Double Blind Placebo Controlled Evaluation of Bioidentical Hormones |
Estimated Enrollment: | 40 |
Study Start Date: | February 2006 |
Estimated Study Completion Date: | October 2009 |
Estimated Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Prempro
|
Drug: Prempro
premarin .45 mg, provera 1.5 mg
|
2: Experimental
Estradiol, estriol, progesterone
|
Drug: estradiol, estriol, progesterone
estradiol 0.5 mg, estriol 2.0 mg, progesterone 100 mg
|
3: Experimental
estriol, progesterone
|
Drug: estriol, progesterone
estriol 2.5 mg, progesterone 100 mg
|
4: Experimental
estradiol,progesterone
|
Drug: estradiol, progesterone
estradiol 0.5 mg, progesterone 100 mg
|
Ages Eligible for Study: | 40 Years to 65 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Treatment with therapeutic doses of any of the following medications more recently than 3 months:
Contact: Jeanne A Drisko, MD | 913-588-6104 | jdrisko@kumc.edu |
United States, Kansas | |
University of Kansas Medical Center | Recruiting |
Kansas City, Kansas, United States, 66160 | |
Contact: Jeanne A Drisko, MD 913-588-6104 jdrisko@kumc.edu | |
Principal Investigator: Jeanne A Drisko, MD |
Principal Investigator: | Jeanne A Drisko, MD | University of Kansas |
Responsible Party: | University of Kansas Medical Center ( Jeanne Drisko ) |
Study ID Numbers: | 9941, GCRC 0024 |
Study First Received: | March 10, 2006 |
Last Updated: | December 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00302731 |
Health Authority: | United States: Food and Drug Administration |
Estrogens, Conjugated (USP) Medroxyprogesterone 17-Acetate Progesterone Benzoates Estradiol 3-benzoate Menopause, Premature |
Estradiol valerate Medroxyprogesterone Estradiol 17 beta-cypionate Polyestradiol phosphate Estradiol Menopause |
Estrogens Antineoplastic Agents, Hormonal Antineoplastic Agents Contraceptive Agents Physiological Effects of Drugs Contraceptives, Oral Hormones, Hormone Substitutes, and Hormone Antagonists Contraceptive Agents, Female |
Reproductive Control Agents Contraceptive Agents, Male Hormones Pharmacologic Actions Progestins Therapeutic Uses Contraceptives, Oral, Synthetic |